Author Archives: Megan Thomas

#Breast cancer #Cancer research #Clinical trials #Solid tumours

New DDW Highlights episode: 27 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week that… Read More

#News

#DDW Highlights podcast

DDW Highlights: 27 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week that… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Last chance to register: Generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#Breast cancer #Cancer research #Clinical trials #Phesi

Breast cancer tops most-studied diseases, study finds 

Phesi has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator platform (Figure 1). The analysis of 67,469 recruiting clinical trials reveals that breast cancer is the world’s most studied disease for the fourth consecutive year… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Cancer immunotherapy #Cancer vaccine #Cell therapy #Immunotherapy

New DDW Highlights podcast: 20 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early… Read More

#News

#DDW Highlights podcast

DDW Highlights: 20 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early… Read More

#Podcasts

#2025 predictions #Artificial intelligence (AI) #Drug discovery #Lab technology #Machine learning

Tech, ML and AI: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Here, the focus is on technology, machine learning (ML) and artificial intelligence (AI). In a prediction piece written for Forbes, contributor Bernard Marr outlined five key technology trends for 2025 across multiple industries1. With… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

Neurons in a brain with Alzheimer's disease
#Drug discovery #Mission Therapeutics #Mitophagy #Neurodegenerative disorders #Neuroscience

Can neurodegenerative diseases be tackled by enhancing mitophagy?

Mission Therapeutics, a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, has announced the publication of a review article titled ‘Targeting mitophagy in neurodegenerative diseases’ in the journal Nature Reviews Drug Discovery. The article outlines the progress scientists have made in identifying that mitochondrial dysfunction is… Read More

#News

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Webinar covers the benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#Cancer drug targets #Collaboration #Drug discovery #Molecular glue degrader #Protein #Rappta Therapeutics #SpringWorks Therapeutics

License agreement for molecular glue targeting PP2A

Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More

#Business & Investment #Cancer Research #News

Meet The Exhibitor
#Events #Meet the Exhibitor #SLAS2025 #Sphere Fluidics #Vodcast

New Meet the Exhibitor vodcast: SLAS2025

The sponsored DDW Meet the Exhibitor Vodcast is a series of in-person interviews from key industry events. Here, Megan Thomas, Multimedia Editor at DDW, interviews Jay Gerlach, VP of Marketing at Sphere Fluidics, in the lead up to SLAS2025 in San Diego. At SLAS2025, you will have… Read More

#News

Meet The Exhibitor
#Events #Meet the Exhibitor #SLAS2025 #Sphere Fluidics #Vodcast

Meet the Exhibitor SLAS2025: Jay Gerlach, Sphere Fluidics

The sponsored DDW Meet the Exhibitor Vodcast is a series of in-person interviews from key industry events. Here, Megan Thomas, Multimedia Editor at DDW, interviews Jay Gerlach, VP of Marketing at Sphere Fluidics, in the lead up to SLAS2025 in San Diego. At SLAS2025, you will have… Read More

#Videos

Multiple myeloma
#Antibody drug conjugate (ADC) #Clinical trials #Heidelberg Pharma #Myeloma

Heidelberg Pharma progresses multiple myeloma ADC

Heidelberg Pharma is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Heidelberg uses the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin… Read More

#News

#Business #Financing #Fundraising #Investment

New DDW Highlights podcast: 13 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up at the end of last year focused on drug… Read More

#News

#DDW Highlights podcast

DDW Highlights: 13 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up at the end of last year focused on drug… Read More

#Podcasts

Cancer cells
#AstraZeneca #Cancer research #Guide #Immune response #Immuno-oncology #Immunotherapy #Immutep #Interview #Oncology #OncologyCancer research

Podcast: Breakthroughs and opportunities in cancer research

This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More

#News